



CLINICAL GUIDELINE

Paediatric IV to Oral Antibiotic Switch Therapy (IVOST)

A guideline is intended to assist healthcare professionals in the choice of disease-specific treatments.

Clinical judgement should be exercised on the applicability of any guideline, influenced by individual patient characteristics. Clinicians should be mindful of the potential for harmful polypharmacy and increased susceptibility to adverse drug reactions in patients with multiple morbidities or frailty.

If, after discussion with the patient or carer, there are good reasons for not following a guideline, it is good practice to record these and communicate them to others involved in the care of the patient.

Version Number:	2
Does this version include changes to clinical advice:	Yes
Date Approved:	17 th November 2020
Date of Next Review:	30 th November 2023
Lead Author:	Susan Kafka
Approval Group:	Antimicrobial Utilisation Committee

Important Note:

The Intranet version of this document is the only version that is maintained. Any printed copies should therefore be viewed as 'Uncontrolled' and as such, may not necessarily contain the latest updates and amendments.

Review need for IV antibiotics DAILY: review & document patient progress/the IVOST plan within 72 hours of IV antibiotic initiation

Are all of the following IVOST criteria met?

- ✓ **CLINICAL IMPROVEMENT** in signs of infection e.g. temperature $\leq 37.9^{\circ}\text{C}$, reduction in the PEWS score, improving SEPSIS
- ✓ **ORAL ROUTE is available reliably** (eating/drinking and no concerns regarding absorption)
- ✓ **UNCOMPLICATED INFECTION** (specialist advice not required prior to IVOST). Certain infections need prolonged IV e.g. CNS infection; Cystic Fibrosis; Endocarditis; Bone/joint infection; Undrainable deep abscess; Bacteraemia.

CRP does NOT reflect severity of illness or the need for IV antibiotics & may remain elevated as the infection improves.

DO NOT use CRP in isolation to assess IVOST suitability. Most infections require ≤ 7 days TOTAL (IV + oral) therapy. Record the intended duration on the medicine Kardex

YES

Can you STOP THERAPY? If antibiotic therapy is still required → **SWITCH TO ORAL.**

First, check the **MICROBIOLOGY** results; can you **NARROW THE ANTIBIOTIC SPECTRUM** based on cultures?

If the patient is being treated in line with the Empiric Infection Management Guidelines

AND there is **NO POSITIVE MICROBIOLOGY** to guide the change then switch to oral as outlined below;

EMPIRIC ORAL SWITCH[■]

DIAGNOSIS [❖]	1 ST LINE	2 ND LINE/PENICILLIN ALLERGY	TOTAL duration (IV + PO)
Resolving sepsis and source unknown	Discuss with micro/ID	Discuss with micro/ID	As per micro/ID
Community-acquired pneumonia (CAP)	Amoxicillin	Azithromycin	5-7 days based on clinical improvement. Give 3 days PO Azithromycin
Aspiration pneumonia	Amoxicillin	Clindamycin	10 days
Severe pneumonia/pneumonia complicating influenza	Co-amoxiclav	Discuss with Micro/ID	Discuss with Micro/ID
Acute mastoiditis	Co-amoxiclav	Clindamycin	14 days
Intra-abdominal sepsis	Co-amoxiclav	Ciprofloxacin & metronidazole	10 days
Upper tract UTI/Pyelonephritis	Cefalexin	Ciprofloxacin	7-10 days
Septic arthritis or Osteomyelitis	Co-amoxiclav (If ≥ 6 yrs consider Flucloxacillin capsules)	Clindamycin	3 weeks for septic arthritis and 4-6 weeks for osteomyelitis
Cellulitis	Flucloxacillin	Clindamycin	7 days
Orbital/Peri-orbital cellulitis	Co-amoxiclav	Clindamycin	7-10 days

NO

Check the microbiology results. Can you NARROW THE SPECTRUM of IV therapy?

Is the patient on IV gentamicin?

- DO NOT** continue IV gentamicin for longer than 4 days (except on the advice of Microbiology/ID). Patients prescribed IV gentamicin for 4 days should have a senior review of their diagnosis, microbiology and clinical progress;
1. Is Gram-negative cover still required? If not, stop gentamicin.
 2. Is there any positive microbiology? If so simplify.
 3. If IV therapy & Gram-negative cover are still required and there is no positive microbiology, discuss with Microbiology/ID.
 4. If gentamicin is required for longer (e.g. endocarditis) seek Microbiology/ID advice & monitor for signs of renal & oto/vestibular toxicity.

❖ Consult an infection specialist (microbiology or infectious diseases) on the switch options for the specific infections listed above OR where empiric IV antibiotic therapy differed from guideline on specialist advice.

■ Consult BNFC for dosing advice